HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Remission maintenance after tocilizumab dose-tapering and interruption in patients with giant cell arteritis: an open-label, 18-month, prospective, pilot study.

AuthorsCarlotta Nannini, Laura Niccoli, Stelvio Sestini, Iashar Laghai, Angela Coppola, Fabrizio Cantini
JournalAnnals of the rheumatic diseases (Ann Rheum Dis) Vol. 78 Issue 10 Pg. 1444-1446 (10 2019) ISSN: 1468-2060 [Electronic] England
PMID31213436 (Publication Type: Clinical Trial, Letter)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • tocilizumab
Topics
  • Adult
  • Antibodies, Monoclonal, Humanized (administration & dosage)
  • Female
  • Giant Cell Arteritis (drug therapy)
  • Humans
  • Induction Chemotherapy (methods)
  • Male
  • Pilot Projects
  • Prospective Studies
  • Time Factors
  • Treatment Outcome
  • Withholding Treatment

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: